This study is being conducted to evaluate the overall safety of lenalidomide (also known as
Revlimid) in patients with lymphoma, and to determine whether it is effective in preventing
this disease from returning after stem cell transplant. This study will also determine the
dose of lenalidomide that can be given without causing severe side effects. Lenalidomide has
not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of
lymphoma. At least 28 people will be enrolled on this study at the University of
Pennsylvania.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania